GEORGE R BLUMENSCHEIN to Proportional Hazards Models
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Proportional Hazards Models.
Connection Strength
0.126
-
Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark. 2011-2012; 10(6):287-98.
Score: 0.050
-
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822.
Score: 0.020
-
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 10; 31(32):4105-14.
Score: 0.015
-
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
Score: 0.015
-
cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77.
Score: 0.013
-
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
Score: 0.013